"Technology Innovation & Entrepreneurship in Israel" - An Evening with Fredric D. Price, Chairman and CEO, Chiasma November 15, 2011

IN CELEBRATION OF GLOBAL ENTREPRENEURSHIP

The Lubin School of Business at Pace University presents: "Technology Innovation & Entrepreneurship in Israel: The Biopharmaceutical Industry," An Evening with Fredric D. Price, Chairman and CEO, Chiasma (Israel). Chiasma is developing new oral drugs for treatment of orphan diseases. Its lead product Octreolin™ (oral octreotide acetate) is in clinical trials for acromegaly.

Come and be inspired by Fredric D. Price, who has:

* Membership on 9 Biotech Boards (past and present)
* Raised more than $500 MILLION in a variety of securities transactions
* Led a total of 18 M&A and licensing transactions
* Built FDA approved facilities
* Had drugs approved in the US as well as in international markets
* 13 issued US patents (Co-inventor)
* BA from Dartmouth College; MBA from the Wharton School of the University of Pennsylvania

About Entrepreneurship@Lubin's Fall 2011 Speaker Series on Technology Entrepreneurship with an Israeli Focus: In addition to Fredric Price, Chairman and CEO of Chiasma, who will present on Tuesday, November 15, Ran Harnevo, Co-Founder & CEO of 5minMedia, will speak on Tuesday, December 13. Yaron Galai, Co-Founder and CEO of Outbrain, spoke on October 11.

International Field Study Course in Israel: The three CEO lecture series is part of an international field study course titled Technology Innovation and Entrepreneurship in Israel, which is being led by Professor Bruce Bachenheimer, Director of Entrepreneurship at Pace University. Classes are being conducted in the fall semester and travel to Israel will be from January 5-15, 2012. Pace students will learn about the key economic and social drivers of technology development and entrepreneurial activity in Israel. Students will also develop an understanding of how international business and globalization is impacting the country.

General Public RSVP: Space limited; to request a seat, e-mail [email protected]